公开(公告)号：US20250121061A1

公开(公告)日：2025-04-17

申请号：US18834896

申请日：2023-03-30

Applicant: VIGENCELL INC.

Inventor： Hyun-Il CHO ,  Jung-Min HA ,  Sang Eun LEE ,  Chung Hyo KANG ,  In Sil SONG

IPC: A61K40/11 ,  A61K40/31 ,  A61K40/42 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to a chimeric antigen receptor including a CD30-derived intracellular signaling domain, immune cells expressing same, and uses thereof. More specifically, the present invention is designed to use a chimeric antigen receptor including a portion of the sequence of TRAF-binding domain within the CD30 domain as an intracellular signaling domain to increase the proliferation and survival of immune effector cells, thereby providing an effect of enhancing antitumor efficacy and cytokine secretion.

公开(公告)号：US20240277775A1

公开(公告)日：2024-08-22

申请号：US18569023

申请日：2021-06-14

Applicant: VIGENCELL INC. ,  THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hyun Jung SOHN ,  Tai Gyu KIM ,  Su Eon KIM ,  Soo Hyun JUNG ,  Hyun ll CHO ,  Bang Geul LIM ,  Eun Ah KIM

IPC: A61K35/51 ,  A61P9/10 ,  C12N5/078

CPC classification number: A61K35/51 ,  A61P9/10 ,  C12N5/0634 ,  C12N2501/125 ,  C12N2501/22

Abstract: The present invention relates to the pharmaceutical use of a cord blood immunosuppressive cell and, more specifically, the present invention provides the use of a human-derived cord blood immunosuppressive cell, which is selected in accordance with analysis of function and phenotype and a classification standard, as a new cell therapy product for anti-inflammation, anti-fibrosis, and prevention or treatment of myocardial infarction.